Skip to main content

Viking Therapeutics emerges as a strong weight loss drug player — or takeover target

Some Wall Street analysts said Viking's experimental obesity treatment may be "best-in-class" following the release of midstage trial data.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.